Respected medical journal the British Medical Journal (BMJ) has reported on alleged data integrity issues with clinical trials that were carried out for Pfizer’s Covid-19 vaccine.
The report was based on information sent from a whistleblower that was backed up by others who worked on the trial. The journal wrote that “…the company falsified data, unblinded patients, employed inadequately trained vaccinators, and was slow to follow up on adverse events reported in Pfizer’s pivotal phase III trial.”
Additionally, a former regional director for Ventavia Research Group, Brook Jackson, provided company documents, audio recordings, emails and photos supporting her claims to the BMJ. Ventavia is a company that was contracted by the pharmaceutical firm to help with the decisive trial.
According to Jackson, staff at Ventavia were overwhelmed by the volume of issues they found. She said that she repeatedly voiced her concerns to superiors about problems such as patient safety, data integrity and poor lab management.
To add to this, Jackson also reported her concerns to the FDA. Later the same day, she was fired on the grounds that she was “not a good fit.” She said it was the first time she had been fired during her 20-year research career.
Among the information provided to the BMJ by Jackson was a recording of a late September meeting in which she met with two directors of Ventavia to discuss a possible FDA inspection. One executive said to Jackson: “We’re going to get some kind of letter of information at least, when the FDA gets here … I know it.”
